...company raises $91M series CMedable Inc. raised $91 million in a series C round led by Sapphire...

...retinal vein occlusion (RVO) after the combination missed the primary endpoint in the Phase III SAPPHIRE...

...Submit NDA YE18 Clearside Biomedical Inc. (NASDAQ:CLSD) Zuprata Retinal vein occlusion (RVO) Top-line Ph III SAPPHIRE...

...Biomedical Inc. (NASDAQ:CLSD) Triamcinolone acetonide Macular edema associated with retinal vein occlusion (RVO) Ph III SAPPHIRE...

...Pfizer Inc. (NYSE:PFE) sold its 49% stake in Chinese JV Hisun-Pfizer Pharmaceuticals Co. Ltd. to Sapphire...
...of our healthcare solutions in China and other markets." Danehy declined to disclose how much Sapphire...

...Pfizer Inc. (NYSE:PFE) sold its 49% stake in Chinese JV Hisun-Pfizer Pharmaceuticals Co. Ltd. to Sapphire...
...of our healthcare solutions in China and other markets." Danehy declined to disclose how much Sapphire...

...to the recommendation. Helsinn gained the small molecule ghrelin agonist through its 2009 acquisition of Sapphire Therapeutics Inc....

...Clearside began the blinded, sham-controlled, U.S. Phase III SAPPHIRE trial to compare suprachoroidal Zuprata plus intravitreal...

...cancer (NSCLC) patients. Helsinn gained the small molecule ghrelin agonist through its 2009 acquisition of Sapphire Therapeutics Inc....

...could not be reached for next steps. Helsinn gained anamorelin through its 2009 acquisition of Sapphire Therapeutics Inc....